新云社 update: China’s National Medical Products Administration has approved iminexifor for injection (brand name Fonokai), a Class 1 innovative drug filed by Suzhou Sinovent Pharmaceutical Technology, for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP). The drug is indicated for patients aged 18 and older with HABP/VABP caused by susceptible Gram-negative bacteria including Klebsiella pneumoniae, the Acinetobacter calcoaceticus-baumannii complex, Pseudomonas aeruginosa and Escherichia coli.
China NMPA Approves Sinovent’s Iminexifor for Hospital-Acquired Pneumonia
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
33m ago
Argentina approves LNG project under large-investment incentive scheme
42m ago
JackYi: Market Drop Tied to Global Financial Risk, Not Crypto Data
1h ago
NDRC Holds Video Meeting on Government Investment Fund Disbursement and Project Reserves
1h ago
Iran says it shot down 58th US MQ-9 Reaper drone over Strait of Hormuz
1h ago
People’s Daily Rebuts Foreign Pessimism on Chinese Economy
1h ago
Bessent Says He Still Lives on Military Base Over Iran Threats




